* Kadcyla approved in Japan, recommended for approval in EU * EU agency also backs Algeta/Bayer prostate cancer drug LONDON, Sept 20 (Reuters) - Roche's new breast cancer drug Kadcyla was approved in Japan on Friday and recommended for approval in Europe, building on February's U.S. g
Read morePlethora Solutions Holdings Chairman Bill Robinson is stepping down from his role at the pharmaceuticals company. Jim Mellon will take over as Chairman with immediate effect temporarily until a successor is found. Robinson, who has been Chairman since 2009, will remain a Non-Executive Director of
Read morePlethora Solutions has secured 2.1m pounds in funding after its subsidiary The Urology Co. fell into administration. The funds were raised through the placing of 106.2m new ordinary shares at a price of 2.0p per share, representing an 8.0% interest. It comes after the company announced it was in
Read moreShares in pharmaceuticals company Plethora Solutions jumped sharply on Thursday after the group reported that it was in 'advanced discussions' with an investor to provide new equity financing to the group. The group, whose share price had recently been declining, added that support was also being s
Read morePlethora Solutions is in urgent discussions with third parties to finance the company's working capital purposes. Shares in the pharmaceutical company plummeted 55.00% to 2.25p at 11:18 following Tuesday's announcement. The company said it remained focused on the development of SD502, a drug for
Read morePlethora Solutions is definitely a small cap stock to watch and in an exclusive interview with Sharecast, Daniel Stewart analyst Vadim Alexandre has reiterated the bull case for the biotech tiddler. Plethora Solutions has a drug, PSD502, aimed at treating premature ejaculation, which has passed two
Read moreHMV Group, the struggling entertainment media seller, has confirmed that it is still pondering what to do with its live music business. HMV added that a number of parties have indicated an interest in acquiring the business. There has been press speculation recently about who might be interested in
Read moreAIM-quoted sexual health products developer and distributor Plethora Solutions has added the pan-European rights for testosterone replacement treatment Striant SR to the UK rights it already has. Plethora has secured the rights from Columbia Laboratories and it will sell the product through its di
Read moreHedge fund manager Charlemagne's assets under management rise have picked up in the past two months to stand at $3.04bn at end August. The modest recovery follows a fall in the first half to $2.8bn, blamed on declining markets. Operating profits were $1.2m, down from $1.3m, with one-off performanc
Read moreLONDON (Dow Jones)--Plethora Solutions Holdings PLC (PLE.LN), a U.K.-based specialty pharmaceutical company, said Monday it has launched a new product, hi-Argenol, for the maintenance and improvement of male sexual health. -Shares closed Friday at 11.75 pence valuing the company at GBP5.21 milli
Read more